From the Journals

AACE issues ‘cookbook’ algorithm to manage dyslipidemia


 

Statement aligns with major guidelines

In general, the 2017 AACE/ACE guidelines and algorithm are “pretty similar” to other guidelines such as the 2018 ACC/American Heart Association (AHA) guidelines for cholesterol management, the 2019 ACC/AHA guidelines for primary prevention of CVD, and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for the management of dyslipidemia, according to Dr. Eckel.

They have “all have now taken into consideration the evidence behind PCSK9 inhibitors,” he noted. “That’s important because those drugs have proven to be effective.”

Two differences, he pointed out, are that the 2019 ESC/EAS guidelines suggest that lipoprotein(a) measurement be considered at least once in every adult’s lifetime, and they recommend apo B analysis in people with high triglycerides but normal LDL (or no higher than 100 mg/dL), to identify additional risk.

*AACE changes its name, broadens focus

Shortly after its algorithm was published, AACE announced that it has a new organization name and brand, the American Association of Clinical Endocrinology, which “more clearly defines AACE as a community of individuals who work together to elevate the practice of clinical endocrinology,” according to an Oct. 20 statement.

The change is meant to acknowledge AACE’s “more modern, inclusive approach to endocrinology that supports multidisciplinary care teams – with endocrinologists leading the way.”

Along with the name change is a new global website. The statement notes that “health care professionals and community members can access all of the valuable clinical content such as guidelines, disease state networks and important education by visiting the pro portal in the top right corner of the site, or by going directly to pro.aace.com.”

Dr. Handelsman discloses that he receives research grant support from Amgen, Applied Therapeutics, AstraZeneca, BMS, Gan & Lee, Novo Nordisk, and Sanofi, and he is a consultant and/or speaker for Amarin, BI-Lilly, and Sanofi.

Dr. Eckel has received consultant/advisory board fees from Kowa, Novo Nordisk, and Provention Bio.

Pages

Recommended Reading

Liberalized European sports cardiology guidelines break new ground
MDedge Internal Medicine
Pesco-Mediterranean diet, fasting ‘ideal’ to reduce CVD risk
MDedge Internal Medicine
Address root causes to manage NASH
MDedge Internal Medicine
VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors
MDedge Internal Medicine
Time-restricted eating shows no weight-loss benefit in RCT
MDedge Internal Medicine
MI recurrences drop, but women underestimate disease risk
MDedge Internal Medicine
Bariatric surgery linked to longer life
MDedge Internal Medicine
Certain statins linked to lower mortality risk in patients admitted for sepsis
MDedge Internal Medicine
Artificially sweetened drinks add to CVD risk
MDedge Internal Medicine
Cannabis may improve liver function in patients with obesity
MDedge Internal Medicine